In the time since the Novartis gene therapy Zolgensma was approved for babies with spinal muscular atrophy, other treatments ...
Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.
LancsLive on MSN18h
'We waited months for answers over our baby's condition - now he'll never be able to walk'Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular ...
To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...
A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.
Independent.ie on MSN17h
‘Every day counts’ – call to add screening for rare muscle-wasting condition to newborns’ ‘heel-prick’ testA majority of people have supported the urgent implementation of early screening for a genetic disease that causes severe ...
A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...
Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...
A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...
Chugai Pharma’s Evrysdi tablets 5mg receives Japanese approval to treat spinal muscular atrophy: Saturday, March 29, 2025, 11:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd. announ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback